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Introduction
Hepatitis B is a serious global infection disease and a major cause 
of mortality and morbidity. It is the 10th leading cause of death, with 
two billion people infected, and an estimated 400 million suffering 
from chronic hepatitis B virus (HBV) infection worldwide [1-5]. HBV 
endemicity has varied widely worldwide. It has been estimated that 
HBV is highly endemic in all of Africa (except Tunisia and Morocco), 
some parts of South America, Alaska, northern Canada and parts of 
Greenland, eastern Europe, the eastern Mediterranean area, south-east 
Asia, China, and the Pacific Islands (except Australia, New Zealand and 
Japan) [6,7]. In the Middle East, Saudi Arabia, Jordan, Oman, Yemen, 
and Palestine are areas classified as of high endemicity; Iraq and the 
United Arab Emirates have intermediate endemicity; whereas Iran, 
Kuwait, and Bahrain have low endemicity [1,4,8]. In re-examining the 
epidemiology of HBV infection, Custer and colleagues undertook a 
structured review of available primary literature for over 30 countries 
worldwide. They found that the prevalence of chronic HBV infection 
ranged from over 10% in some Asian and Western Pacific countries to 
under 0.5% in the United States and northern European countries [9].
Unsafe blood transfusion is one of the routes of transmission for 
HBV infection. Despite, all blood donations being tested routinely 
for hepatitis B surface antigen (HBs-Ag) as a marker of transmissible 
HBV, occasional cases of post-transfusion hepatitis B virus infection 
are common [8,10-13]. Generally occult HBV infection is defined as 
the detection of HBV-DNA in the serum or tissue of subjects who have 
negative test for HBs-Ag [2]. In addition, antibodies to hepatitis B core 
(HBc) antigen are marker to acute, chronic and resolved HBV infection 
that remain detectable forever. Consequently anti HBc is detected in 
anyone who has been infected with HBV, while the level of HBs-Ag in 
the circulation becomes too low to be distinguished [14]. The frequency 
of this cryptic infection appears to be varies considerably according to 
prevalence of the infection. In relatively low prevalence areas of HBV 
infection such as Europe and North America, than 5% of blood donors 
are characterised as having occult hepatitis B. In contrast, occult HBV 
is the major cause of transfusion transmitted HBV infection in high 
prevalence areas such as Ghana [1,2, 10,15,16]. In Iran data on Occult 
hepatitis B are scare. There are only three studies which demonstrated 
evidences of HBV-DNA detection in blood donor samples positive for 
Anti-HBc. Those identified found a range between 11.3% and 28.6 % 
HBV
DNA positivity among Anti-HBc+ blood donor samples (Table 1). 
A map of Iran provinces mentioned above is shown in Figure 1. These 
studies conducted in different urban areas of Iran and only one of them 
[12] considered subjects’ sex and age. Given that the multiethnic nature 
of Iran population can affect the epidemiology of blood-borne occult 
hepatitis B [4], establishing the prevalence of occult hepatitis B among 
blood donors in each province, including both urban and rural areas, 
of Iran can be an appropriate indicator for the risk of transmitting HBV 
through blood transfusion. Moreover, Iran, like many other countries in 
the Middle East, has a large number of major beta-thalassemia patients 
that require regular multi-transfusion for survival [17]. These patients 
are at high risk for blood transmitted viral infections such as hepatitis 
B [18]. The purpose of this study was to assess the anti-HBc positivity 
and presence of HBV-DNA in serum sample of healthy blood donors 
negative for HBsAg stratified by sex and age. Since anti-HBc detection 
is not a routine test in Iran Blood Bank, this study assessed whether 
anti-HBc could be adopted as a screening assay for the donated blood.
Materials and Methods
Procedure
Blood samples of blood donors used in the study were from the 
whole province of Kerman, Iran. All blood samples were collected over 
a one year period (2008). Blood donors were interviewed and medically 
examined as a part of the standard screening process for blood donation 
in Iran Blood Banks. For example, those with high risk behaviours 
such as unsafe sexual contact or intravenous drug use and those who 
recently received HBV vaccination were excluded from donating blood. 
Consequently they were not included in the current study. As usual 
process for all blood donated, hepatitis B (surface) antigen (HBs-Ag), 
antibody to HCV (anti-HCV), Rapid Plasma Reagin (RPR) test, and 
antibody to human immune deficiency virus (anti-HIV) were tested. 
To conduct the study, all samples negative for HBs-Ag and other tests 
mentioned above were tested for Hepatitis B (core)–Antigen (anti-
HBc). Samples with repeated anti-HBc positivity were considered to be 
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Reference Country/City Number screened Anti-HBc+ (%) DNA+ (%)
[25] Greece 6696 Na* 0
[26] UK 103869 586(0.56) 0
[27] USA 4885732 40998(0.84) 3.7
[15] Ghana 242 110(45.5) 12.7
[1] India 5511 188(18.3) 21.0
[28] Lebanon 1027 203(3.7) 5.4
[12] Iran/Shiraz 2000 6.55 12.2
[21] Iran/Isfahan 545 8.00 11.26
 [13] Iran/Rafsanjan 270 5.18 28.57
*Not mentioned
Table 1: Reported Prevalence of HBV-DNA+ in anti-HBC+ blood donors.
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anti-HBc+ and were tested for HBV-DNA. This study was approved by 
Kerman University Medical Sciences Ethics committee.
Serological assays
HBs-Ag and anti-HBc were detected by enzyme immunoassay 
available in Iran Blood Bank. HBs-Ag testing was conducted with 
a commercial EIA (Enzygost HBsAg 6.0) and anti-HBC testing 
was conducted with another commercial EIA (Enzygost Anti-HBc 
monoclonal). All serological tests were performed by a laboratory staff 
that had been trained before by the manufacturer’s representative.
PCR assay
Preparation of DNA samples from the sera-strict measures was 
adopted to prevent any contamination [19]. Serum HBV DNA was 
assayed according to the protocol recommended by the manufacturer.
DNA extraction
DNA was extracted from 200ml samples by DNA template 
extraction kit (Roche, Germany), was eluted in 200 ml elution buffer 
and then was freezed in - 80 centigrade degree.
PCR
 For detection of HBV-load in samples, we used Roboscreen HBV-
detection kit (Germany, Roboscreen) with three HBV-DNA, positive 
and negative standard controls (using Corbett Research Australia, 
USA). Samples with ≥20 copies/ml were considered to be positive. 
Sensitivity and specificity for this test were 100% and 98% respectively.
Biochemical tests
Performing biochemical tests was not a part of the study aims. 
However, considering the authors ethical responsibility toward the 
participants with positive HBV DNA PCR results, we invited them for 
a free follow-up management. Therefore, biochemical factors such as 
aspartate aminotransferase (AST=SGOT), alanine amino transferase 
(ALT=SGPT), prothrombin time (pt) and international normalized 
ratio (INR) were performed and also essential treatment and/or further 
follow up, based on medical indications, were also prepared.
Statistical analysis
Using SPSS software version 10.0 was performed to analyse the 
data. Descriptive tables and summary statistics were constructed to 
provide basic characteristics of the subjects in the study.
Results
Serological tests
During the time frame for the study, a total of 1525 donation blood 
negative for HBs-Ag and all other routine blood donor screening assays 
were given to kerman blood bank centres. Of whom 1326 (87.0%) of 
blood samples were from men (age range 18-50yr, mean ± SD: 31±8yr) 
and 199 (13.05%) were from women (age range 21-48yr, mean ± SD: 
30±6yr). Eight percent (121/1525) of them were positive for Anti-HBc, 
and all were from males (Table 2). 
HBV-DNA was detected in 36 out of 121 anti-HBc specimens 
(29.7%).
Positive predictive value for anti-HBc was 83%.
Biochemical markers
Liver markers including aspartate aminotransferase (AST) and 
alanine aminotransferase (ALT) were performed on HBV-PCR 
positive samples. The tests’ results were in 32.4% of samples higher than 
the upper range of normal levels for these tests in clinical diagnostic 
settings. 4.4% of subjects had abnormal PT or INR (Figure 2). Positive 
predictive value for liver markers was 35.3 %.
Discussion
In the present study, frequency of anti-HBc positivity and presence 
of HBV-DNA in sera of healthy blood donors negative for HBS-Ag and 
all other routine blood donor screening assays from Kerman province 
were investigated. 7.9% of them were positive for anti-HBc and all were 
from males. None of the women’s blood samples were found as having 
detected DNA for hepatitis B virus. Among studies conducted in Iran 
only one study stratified in blood donors by gender.6% of men and 
11.6% of women found to be positive for Anti-HBc and negative for 
HBs-Ag [12]. Our finding is consistent with a previous result by Isfahan 
in the central of Iran [21], but it is slightly higher than results from 
blood donors in Shiraz, in the south west of Iran [12], Hamadan in the 
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Figure 2: The biochemical results among HBV DNA positive in anti-HBc only 
blood donors in Kerman.
Sex Age Number screened (%) Anti-HBc+ (%)
Anti-HBc+ & HBV-
DNA+ (%)
Male 31±8yr 1326(87%) 121(9.13%) 29.75%
Female 30±6yr 199(13%) 0(0%) 0%
Table 2: HBV-DNA+ in anti-HBC+ blood donors in Kerman province, Iran.
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Northwest of Iran [22], and Rafsanjan which is a small city of Kerman 
province [13]. The prevalence of anti-HBc in our study was relatively 
higher than other blood donor population in Iran and some countries 
that are classified as having low endemicity for hepatitis B infection. 
These dissimilar findings could be the result of regional differences of 
the prevalence of HBV infection in Iran [23] (Figure 1). 
In this study the frequency of HBV-DNA+ mong anti-HBc positive 
blood donors was 29.7% which is similar to that reported by Rafsanjan 
and Isfahan [13]. However this result is significantly higher than 
two other studies carried out in Shiraz and Isfahan (Table 1). This 
dissimilarity in the frequency of occult HBV in different geographical 
areas in Iran may be attributed to ethnic diversity and PCR detection 
with different sensitive assays. The frequency of HBV-DNA+ also 
varies considerably according to the prevalence of the hepatitis B virus 
infection. Current study demonstrated that, the proportion of HBV 
DNA positive donors is higher than in Europe and USA but relatively 
similar to other regions in the Middle East.
In blood donors with anti-HBc, most reports did not mention 
biochemical marker levels such as ALT as donors were asymptomatic. 
However, studies conducted prior to the availability of sensitive HBV-
DNA assays showed that deferring HBs-Ag negative blood donors with 
elevated ALT decreased HBV transmission [24]. We performed some 
biochemical tests for PCR positive samples. The tests’ results were in 
32.4% of samples higher than the upper range of normal levels for these 
tests in clinical diagnostic settings. In particular, positive predictive 
value for liver markers was 35.3 %. In a study of anti-HBc and HBV-
DNA detection in blood donors negative for hepatitis B virus surface 
antigen in Shiraz, liver marker test results were all in normal ranges 
except in 4 of 16 (25%) of HBV-DNA positive subjects. Therefore an 
association between occult HBV and elevated ALT in the absence of 
other causes of liver disease such as HCV infection and alcohol abuse 
may be proposed.
Conclusion
We found a positive relationship between anti-HBc positivity and 
detection of HBV-DNA in serum samples of HBs-Ag negative blood 
donors. Currently a number of countries including United States 
screen all donations for anti HBc which is not mandatory in some 
other countries such as Iran [25]. Nevertheless it has been argued that 
the exclusion of anti-HBc positive donors is impractical in countries 
where HBV infection is prevalent and more than 20 percent of the 
population are positive for anti-HBc. At the present Iran is classified 
as having a low endemicity for hepatitis B infection and 7.93% of blood 
donors in the study were found to be positive for anti-HBc. Among 
them 30% was found to have detected HBV-DNA. In addition, while 
missing anti-HBs test might be a weaknesses of our study, considering 
lack of published data in humans, absence of any agreement among 
professionals regarding the relationship between HBV DNA detection 
and infectivity of the transfused units in humans with and with ought 
anti-HBs, and also taking into account that various blood components 
contain of plasma, it should be considered that any unit with detectable 
HBV DNA can potentially infect transfusion recipients with HBV. 
Therefore, to limit the transfusion transmission risk of occult hepatitis 
B virus in Iran blood banks, we conclude that introducing anti HBc 
screening maybe practical.
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